Alecensa
Drug - Alecensa® (alectinib) [Genentech, Inc.]
December 2017
Therapeutic area - Oncology
Approval criteria
- Patient must be 18 years of age or older AND
- Patient must have a diagnosis of anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test
Quantity limit
Maximum of 240 capsules per 30 days.
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411